Condition: Heart Failure With Preserved Ejection Fraction · Inflammation · Sponsor: VA Office of Research and Development
This project will evaluate the impact of L-Citrulline, tetrahydrobiopterin (BH4), and atorvastatin administration on physical capacity and vascular function in Veterans with heart failure with preserved ejection fraction (HFpEF).
This description comes directly from the study's public registry record.
David W Wray, PhD · (801) 582-1565 · David.Wray2@va.gov
Misti R Seppi, MBA BS AAS · (801) 582-1565 · Misti.Seppi@va.gov
Always discuss trial participation with your own doctor first.
| VA Salt Lake City Health Care System, Salt Lake City, UT | Salt Lake City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06312748